Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Alphs

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Innovations in Clinical Neuroscience|July 15, 2016
Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders, David Daniel, Amir Kalali, et al.
Innovations in Clinical Neuroscience|August 12, 2022
SIBAT-A Computerized Assessment Tool for Suicide Ideation and Behavior: Development and Psychometric PropertiesLarry Alphs, Dong-Jing Fu, David Williamson, et al.
Archives of General Psychiatry|January 7, 2003
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)Herbert Y Meltzer, Larry Alphs, Alan I Green, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Considerations for the assessment of suicidal ideation and behavior in older adults with cognitive decline and dementiaLarry Alphs, H Robert Brashear, Phillip Chappell, et al.
Schizophrenia Bulletin Open|August 15, 2024
Remote Assessment of Negative Symptoms of SchizophreniaDavid G Daniel, Alex S Cohen, Dawn Velligan, et al.
JAMA Psychiatry|September 10, 2025
ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression: The ENLIGHTEN Randomized Clinical TrialGang Wang, Mario Aguado, Matthew A Spear, et al.
Schizophrenia Bulletin|August 30, 2008
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?Aaron S Kemp, Nina R Schooler, Amir H Kalali, et al.
The American Journal of Psychiatry|February 3, 2007
Comments on "Presidential address: advocacy as leadership"Cathryn Clary, Antony Loebel, Ilise Lombardo, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 5, 2024
Methods for Neuroscience Drug Development: Guidance on Standardization of the Process for Defining Clinical Outcome Strategies in Clinical TrialsSilvia Zaragoza Domingo, Jordi Alonso, Montse Ferrer, et al.
Schizophrenia Research|September 14, 2013
Issues and perspectives in designing clinical trials for negative symptoms in schizophreniaStephen R Marder, Larry Alphs, Ion-George Anghelescu, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Innovations in Clinical Neuroscience|July 15, 2016
Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders, David Daniel, Amir Kalali, et al.
Innovations in Clinical Neuroscience|August 12, 2022
SIBAT-A Computerized Assessment Tool for Suicide Ideation and Behavior: Development and Psychometric PropertiesLarry Alphs, Dong-Jing Fu, David Williamson, et al.
Archives of General Psychiatry|January 7, 2003
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)Herbert Y Meltzer, Larry Alphs, Alan I Green, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Considerations for the assessment of suicidal ideation and behavior in older adults with cognitive decline and dementiaLarry Alphs, H Robert Brashear, Phillip Chappell, et al.
Schizophrenia Bulletin Open|August 15, 2024
Remote Assessment of Negative Symptoms of SchizophreniaDavid G Daniel, Alex S Cohen, Dawn Velligan, et al.
JAMA Psychiatry|September 10, 2025
ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression: The ENLIGHTEN Randomized Clinical TrialGang Wang, Mario Aguado, Matthew A Spear, et al.
Schizophrenia Bulletin|August 30, 2008
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?Aaron S Kemp, Nina R Schooler, Amir H Kalali, et al.
The American Journal of Psychiatry|February 3, 2007
Comments on "Presidential address: advocacy as leadership"Cathryn Clary, Antony Loebel, Ilise Lombardo, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 5, 2024
Methods for Neuroscience Drug Development: Guidance on Standardization of the Process for Defining Clinical Outcome Strategies in Clinical TrialsSilvia Zaragoza Domingo, Jordi Alonso, Montse Ferrer, et al.
Schizophrenia Research|September 14, 2013
Issues and perspectives in designing clinical trials for negative symptoms in schizophreniaStephen R Marder, Larry Alphs, Ion-George Anghelescu, et al.
Pageof 12